Journals Library

An error occurred retrieving content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

This trial showed that the intervention, targeting reasoning, was effective at reducing paranoia in people with schizophrenia-spectrum psychosis.

{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Philippa Garety 1,2,*, Thomas Ward 1,2, Richard Emsley 3, Kathryn Greenwood 4,5, Daniel Freeman 6,7, David Fowler 4,5, Elizabeth Kuipers 1,2, Paul Bebbington 8, Graham Dunn 9,, Amy Hardy 1,2

1 Department of Psychology, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK
2 South London and Maudsley NHS Foundation Trust, London, UK
3 Department of Biostatistics and Health Informatics, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK
4 School of Psychology, University of Sussex, Brighton, UK
5 Sussex Partnership NHS Foundation Trust, Worthing, UK
6 Department of Psychiatry, Oxford University, Oxford, UK
7 Oxford Health NHS Foundation Trust, Oxford, UK
8 Division of Psychiatry, University College London, London, UK
9 Centre for Biostatistics, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
* Corresponding author Email: Philippa.garety@kcl.ac.uk

In memoriam

In memoriam

Declared competing interests of authors: Philippa Garety and Richard Emsley are part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. Richard Emsley is supported by a NIHR Research Professorship (NIHR300051) and declares membership of the NIHR Health Technology Assessment Clinical Evaluation and Trials funding committee (March 2018 to present) and the NIHR Clinical Trials Unit Standing Advisory Committee (January 2020 to present). Daniel Freeman is supported by a NIHR research professorship (NIHR-RP-2014-05-003) and the NIHR Oxford Health Biomedical Research Centre (BRC-1215-20005) and declares personal fees from a University of Oxford spin-out company, Oxford VR (Oxford, UK), outside the submitted work.

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

 

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions